Piper Jaffray analyst Sarah James raised her price target for Henry Schein to $80 from $72 after traveling with management. The analyst walked away more bullish on the company's long-term margin expansion and value added services growth. She sees an increasing differentiation on Schein operations from competitors that could drive "outsized" share gains, better morale, and recruiting. Further, the removal of legal overhang and low exposure to healthcare reform will drive increasing investor interest, James tells investors in a research note. She keeps an Overweight rating on Henry Schein.